dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade Estadual de Campinas (UNICAMP)
dc.contributorUniversidade Federal do ABC (UFABC)
dc.date.accessioned2014-05-27T11:27:26Z
dc.date.accessioned2022-10-05T18:40:08Z
dc.date.available2014-05-27T11:27:26Z
dc.date.available2022-10-05T18:40:08Z
dc.date.created2014-05-27T11:27:26Z
dc.date.issued2013-01-01
dc.identifierJournal of Pharmaceutical Sciences, v. 102, n. 1, p. 215-226, 2013.
dc.identifier0022-3549
dc.identifier1520-6017
dc.identifierhttp://hdl.handle.net/11449/74101
dc.identifier10.1002/jps.23350
dc.identifierWOS:000312145900023
dc.identifier2-s2.0-84870673040
dc.identifier0000-0002-2042-018X
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3923065
dc.description.abstractThe objective of this work was to develop a modified release system for the local anesthetic lidocaine (LDC), using poly(ε-caprolactone) (PCL) nanospheres (NSs), to improve the pharmacological properties of the drug when administered by the infiltration route. In vitro experiments were used to characterize the system and investigate the release mechanism. The NSs presented a polydispersion index of 0.072, an average diameter of 449.6nm, a zeta potential of -20.1mV, and an association efficiency of 93.3%. The release profiles showed that the release of associated LDC was slower than that of the free drug. Atomic force microscopy analyses showed that the spherical structure of the particles was preserved as a function of time, as well as after the release experiments. Cytotoxicity and pharmacological tests confirmed that association with the NSs reduced the toxicity of LDC, and prolonged its anesthetic action. This new formulation could potentially be used in applications requiring gradual anesthetic release, especially dental procedures. © 2012 Wiley Periodicals, Inc.
dc.languageeng
dc.relationJournal of Pharmaceutical Sciences
dc.relation3.075
dc.relation0,984
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectAnalgesia
dc.subjectAnesthetic activity
dc.subjectControlled release
dc.subjectDrug release
dc.subjectLidocaine
dc.subjectNanoparticles
dc.subjectNanospheres
dc.subjectNanotechnology
dc.subjectPoly(ε-caprolactone)
dc.subjectPolymeric drug carrier
dc.subjectlidocaine
dc.subjectnanosphere
dc.subjectpolycaprolactone
dc.subjectanimal experiment
dc.subjectanimal tissue
dc.subjectatomic force microscopy
dc.subjectcontrolled study
dc.subjectcytotoxicity
dc.subjectdrug formulation
dc.subjectdrug release
dc.subjectdrug structure
dc.subjectin vitro study
dc.subjectmale
dc.subjectmouse
dc.subjectnonhuman
dc.subjectzeta potential
dc.subjectAnesthetics, Local
dc.subjectAnimals
dc.subjectBALB 3T3 Cells
dc.subjectCell Survival
dc.subjectChemistry, Pharmaceutical
dc.subjectDelayed-Action Preparations
dc.subjectDose-Response Relationship, Drug
dc.subjectDrug Carriers
dc.subjectDrug Stability
dc.subjectFibroblasts
dc.subjectHydrogen-Ion Concentration
dc.subjectKinetics
dc.subjectMale
dc.subjectMice
dc.subjectMicroscopy, Atomic Force
dc.subjectMotor Activity
dc.subjectNerve Block
dc.subjectPain Threshold
dc.subjectParticle Size
dc.subjectPolyesters
dc.subjectReaction Time
dc.subjectSciatic Nerve
dc.subjectSolubility
dc.subjectTechnology, Pharmaceutical
dc.titlePreparation and characterization of poly(ε-caprolactone) nanospheres containing the local anesthetic lidocaine
dc.typeArtigo


Este ítem pertenece a la siguiente institución